{"id":"ser-109","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL379810","moleculeType":"Small molecule","molecularWeight":"192.17"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SER-109 contains purified spores from a consortium of commensal Bacillus species that colonize the gut and restore microbial diversity. By re-establishing a healthy microbiome, it reduces the risk of C. difficile recurrence by outcompeting pathogenic strains and restoring colonization resistance. This approach addresses the underlying dysbiosis that predisposes patients to recurrent CDI.","oneSentence":"SER-109 is a spore-based microbiome therapeutic that restores healthy gut bacterial composition to prevent recurrent Clostridioides difficile infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:01.099Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Recurrent Clostridioides difficile infection (rCDI) in adults"}]},"trialDetails":[{"nctId":"NCT02437500","phase":"","title":"Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)","status":"APPROVED_FOR_MARKETING","sponsor":"Seres Therapeutics, Inc.","startDate":"","conditions":"Clostridioides Difficile Infection","enrollment":""},{"nctId":"NCT03183128","phase":"PHASE3","title":"ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection","status":"COMPLETED","sponsor":"Seres Therapeutics, Inc.","startDate":"2017-07-10","conditions":"Clostridium Difficile Infection","enrollment":182},{"nctId":"NCT03183141","phase":"PHASE3","title":"ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"Seres Therapeutics, Inc.","startDate":"2017-10-23","conditions":"Clostridioides Difficile Infection","enrollment":263},{"nctId":"NCT02437487","phase":"PHASE2","title":"SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)","status":"COMPLETED","sponsor":"Seres Therapeutics, Inc.","startDate":"2015-05","conditions":"Clostridium Difficile","enrollment":89}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"DIARRHOEA"}],"_approvalHistory":[],"publicationCount":74,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Purified Eubacterial Spores, Encapsulated","Firmicutes spores","Eubacterial Spores, Purified Suspension, Encapsulated"],"phase":"phase_3","status":"active","brandName":"SER-109","genericName":"SER-109","companyName":"Seres Therapeutics, Inc.","companyId":"seres-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"SER-109 is a spore-based microbiome therapeutic that restores healthy gut bacterial composition to prevent recurrent Clostridioides difficile infection. Used for Recurrent Clostridioides difficile infection (rCDI) in adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}